



## PRESS RELEASE

### Revotar receives new composition-of-matter patent for Bimosiamose in the US

**BERLIN/Hennigsdorf (Germany), November 2<sup>nd</sup>, 2011** - Revotar Biopharmaceuticals AG today announced that it has been granted a strategically important patent on a novel crystalline form of its pan-selectin antagonist Bimosiamose by the US Patent & Trademark Office (USPTO). This patent ("Crystalline Forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyloxy)-phenyl] hexane", US 8,039,601) covers a new polymorph form of the pan-selectin antagonist and pharmaceutical compositions and complements the patent portfolio which Revotar is holding around this important product for the treatment of COPD and other chronic and acute respiratory diseases. It generates further composition-of-matter for Bimosiamose and enhances the existing protection of the drug. "For the life cycle of Revotar's most advanced drug candidate Bimosiamose on the US market the issuance of this patent is of strategic importance as it extends the protection of the compound beyond the existing intellectual property rights until 2027", comments Dr. Martin Pöhlchen, CEO of Revotar. "We also believe that this patent qualifies as a basis for a patent term extension up to five years beyond 2027", he added.

#### About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting the lung. According to the WHO, estimated 64 million people have COPD worldwide in 2004. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that COPD will become the third leading cause of death worldwide by 2030. In 2010, the global COPD market recorded sales of approximately 11 billion US\$. There is a high unmet medical need in drugs modifying the underlying inflammation in COPD.

#### About Revotar Biopharmaceuticals AG

Revotar recently announced that it successfully completed a multi-center Phase II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD).



Data have been presented in the late breaking news session at the recent annual congress of the European Respiratory Society (ERS) in Amsterdam end of September and were presented by the research group of Prof. Helgo Magnussen. As previously released, inhalation of Bimosiamose for 28 days on top of standard bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD (GOLD II-III). It led to a broad and significant attenuation of airway inflammation and a trend towards lung function improvement.

Revotar develops innovative drugs for inflammatory indications such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in COPD, asthma, and psoriasis with a good safety and efficacy profile in over 300 patients and volunteers. Furthermore Revotar has two preclinical programs addressing respiratory and other inflammatory diseases.

Contact Address:

Dr Martin Pöhlchen, CEO  
Revotar Biopharmaceuticals AG  
Neuendorfstr. 24a  
D-16761 Hennigsdorf / Germany  
Phone: +49-3302-2025010  
Fax: +49-3302-2025030  
Email: [info@revotar.com](mailto:info@revotar.com)  
[www.revotar.com](http://www.revotar.com)